Registry of "early latecomer" patients with acute ST-segment elevation myocardial infarction at the Instituto Nacional Cardiovascular INCOR - Peru.

OBJECTIVE: To assess the features of asymptomatic patients with acute ST segment elevation myocardial infarction who presents to the emergency with more than 12h of evolution, and if there is a benefit of an invasive versus medical therapy. METHODS: Retrospective, cohort study from January 2012 to December 2014, we compare the outcomes at 6 and 12 months of follow up of the invasive group versus the conservative group. RESULTS: There were no differences in outcomes at 12 months between an invasive versus a conventional strategy; but, looking at the reperfusion state, we found more risk of death and heart failure at 12 months in the no-reperfused group versus the reperfused group (40% versus 0%, OR: 2, CI: 1.2-3.1, p=0.028 for mortality and 53% versus 0%, OR: 2.2, CI: 1.3-3.98, p=0.007 for heart failure). CONCLUSIONS: In patients with ST elevation acute myocardial infarction with more than 12h of evolution, the invasive strategy with optimal reperfusion is better than the conservative management or no reperfusion in terms of less mortality and heart failure at 12 months of follow up.

Registry of "early latecomer" patients with acute ST-segment elevation myocardial infarction at the Instituto Nacional Cardiovascular INCOR - Peru / Registro de pacientes con infarto agudo de miocardio con elevación del ST de más de 12 horas de evolución "early latecomers" en el Instituto Nacional Cardiovascular INCOR-Perú

Abstract Objective To assess the features of asymptomatic patients with acute ST segment elevation myocardial infarction who presents to the emergency with more than 12 h of evolution, and if there is a benefit of an invasive versus medical therapy. Methods Retrospective, cohort study from January 2012 to December 2014, we compare the outcomes at 6 and 12 months of follow up of the invasive group versus the conservative group. Results There were no differences in outcomes at 12 months between an invasive versus a conventional strategy; but, looking at the reperfusion state, we found more risk of death and heart failure at 12 months in the no-reperfused group versus the reperfused group (40% versus 0%, OR: 2, CI: 1.2-3.1, p = 0.028 for mortality and 53% versus 0%, OR: 2.2, CI: 1.3-3.98, p = 0.007 for heart failure). Conclusions In patients with ST elevation acute myocardial infarction with more than 12 h of evolution, the invasive strategy with optimal reperfusion is better than the conservative management or no reperfusion in terms of less mortality and heart failure at 12 months of follow up.

Resumen Objetivo Evaluar las características de pacientes con síndrome coronario agudo con elevación del segmento ST asintomáticos con más de 12 horas de evolución y si existe o no beneficio de la terapia invasiva versus el manejo médico en el seguimiento. Método Estudio retrospectivo, de cohortes desde enero 2012 a diciembre 2014, se comparó los eventos adversos a 6 y 12 meses de seguimiento del grupo en terapia invasiva versus manejo conservador. Resultados No se encontró diferencia entre la estrategia invasiva versus convencional al seguimiento a los 12 meses. Sin embargo comparando el resultado de reperfusión, se encontró mayor riesgo de muerte y falla cardiaca a 12 meses en el grupo no reperfundido versus el reperfundido (40% vs 0%, OR 2, IC: 1.2-3.1, p = 0.028 para mortalidad y 53% vs 0%, OR: 2.2, IC: 1.3-3.98, p = 0.007 para falla cardiaca). Conclusiones En pacientes con infarto agudo de miocardio ST elevado de más de 12 horas de evolución asintomáticos, la estrategia invasiva con resultados óptimos de reperfusión es mejor que el manejo conservador o no reperfusión en cuanto a disminución de la mortalidad y falla cardiaca en el seguimiento al año.